Biomimetic Nanotechnology for SARS-CoV-2 Treatment

More than 600 million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the pandemic of coronavirus disease 2019 (COVID-19). In particular, new waves of COVID-19 caused by emerging SARS-CoV-2 variants pose new health risks to the global population. Nanotechnology has developed excellent solutions to combat the virus pandemic, such as ACE2-based nanodecoys, nanobodies, nanovaccines, and drug nanocarriers. Lessons learned and strategies developed during this battle against SARS-CoV-2 variants may also serve as inspiration for developing nanotechnology-based strategies to combat other global infectious diseases and their variants in the future.

Automated summary

Over 600 million people worldwide have been infected with SARS-CoV-2, resulting in the COVID-19 pandemic. New waves of COVID-19 caused by emerging SARS-CoV-2 variants pose new health risks. Nanotechnology offers effective solutions, such as ACE2-based nanodecoys, nanobodies, nanovaccines, and drug nanocarriers. Lessons and strategies from battling SARS-CoV-2 variants may inspire nanotechnology-based strategies for future global infectious diseases and their variants.